ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*JBDM Ver 1.7.2 (20 November 2019) - 2999001/02978845CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120200617W172 73deBibliographieenBibliographyfrBibliographieEP14713467.0201403272015102320170619enenen1316147420130327EP1317307820130620EP1319982620131230EP2020061720202520160203201605202004292020182020031620200617202025C12N 15/113 20100101AFI20151026BHEP C07H 21/02 20060101ALI20151026BHEP A61K 31/713 20060101ALI20151026BHEP A61P 35/00 20060101ALI20151026BHEP deMODIFIZIERTE TGF-BETA-OLIGONUKLEOTIDEenMODIFIED TGF-BETA OLIGONUCLEOTIDESfrOLIGONUCLÉOTIDES DE TGF-BETA MODIFIÉSEP-A2- 1 008 649EP-A2- 2 399 611WO-A1-2011/154542WO-A2-2005/084712STANTON ROBERT ET AL: "Chemical Modification Study of Antisense Gapmers", NUCLEIC ACID THERAPEUTICS, vol. 22, no. 5, October 2012 (2012-10), pages 344-359, XP055075730,MIHO TAKAGI-SATO ET AL: "Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression", NUCLEIC ACIDS SYMPOSIUM SERIES, no. 50, 2006, pages 319-320, XP003021650, ISSN: 0261-3166GORDON, K. & BLOBE, G.: "Role of transforming growth factor-beta superfamily signaling pathways in human disease.", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, vol. 1782, no. 4, 11 February 2008 (2008-02-11), pages 197-228, XP022540518, ISSN: 0925-4439 cited in the applicationJASCHINSKI, FrankChristine-Zeiske-Weg 1282178 PuchheimDEJANICOT, MichelAvenue Winston Churchill 1491180 BrusselsBEUHLMANN, EugenZum Talblick 3161479 GlashüttenDEISARNA Therapeutics GmbH101855370P101116EP01Schellingstraße 109a80798 MünchenDEV.O.101551773P.O. Box 879302508 DH Den HaagNLALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20151023ME20151023EP201405622120140327enWO201415483520141002201440